Mercury Bio Develops New Biomolecular Drug Delivery Platform – Yahoo Finance

SANTA FE, N.M., Oct. 26, 2022 /PRNewswire/ — Harnessing the power of naturally occurring extracellular vesicles, New Mexico-based biotech company Mercury Bio has developed patent-pending technology that will enable highly targeted delivery of both RNA therapeutics, and small-molecule drugs, to targeted diseased cells.
The recent, revolutionary use of RNA in the COVID vaccines has ushered in the broader potential of RNA therapeutics to cure many diseases, not just provide protection against them. The major challenge for RNA therapeutics is being able to deliver them to the precise cells in our body which are in need of the RNA to either silence or upregulate genes responsible for a particular disease.
Similarly, many small-molecule pharmaceutical drugs currently on the market are challenged by off-target delivery, which can result in negative side effects and low bioavailability. To complicate matters further, small-molecule drugs are often destroyed or eliminated by the body before they even have a chance to deliver treatment.
All of this adds up to a problem of ineffective drug delivery.
As Bruce McCormick, CEO of Mercury Bio states, “Curing many diseases now does not require new drugs; it needs new drug delivery systems. The ability to deliver RNA and small-molecule drugs directly to target cells is a reality that will change the way we approach disease.”
To address the problem, Mercury Bio has developed a biomolecular, advanced drug delivery system (ADDS™) that will reduce the roadblocks RNA therapeutics and small-molecule drugs encounter in vivo. By engineering naturally occurring vesicles to encapsulate RNA therapeutics and small-molecule drugs, and by modifying these vesicles to display a cell-specific targeting mechanism, challenges with drug potency and drug targeting specificity are simultaneously addressed.
Like many scientific developments, this ADDS™ was the fortuitous byproduct of a different focus. Early work researching an RNA treatment for COVID revealed that off-target drug-delivery was a critical limiting factor, just as it is with small-molecule drugs. It became clear that innovating an effective advanced drug delivery system could have very broad applications beyond combatting COVID. So, while the company began as Spartina Biotechnologies, it changed its name to Mercury Bio in 2022 to reflect its rapidly increasing focus on molecular drug-delivery technologies, taking inspiration for its new name from the Roman god of messages and communication.
Mercury Bio is now broadening operations in Santa Fe, New Mexico — adding new scientists to the team and expanding its laboratory facilities. With a growing IP portfolio that could resolve one of the most significant challenges facing an industry estimated to grow to $37 billion by 2030, Mercury Bio is also actively assembling private equity investments and pursuing new research collaborations.
To learn more about these opportunities, and to better understand how advanced drug delivery systems could profoundly impact the potency of next-generation pharmaceuticals, visit www.mercurybio.com
Contact:
Bruce McCormick
800-274-8533
347459@email4pr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/mercury-bio-develops-new-biomolecular-drug-delivery-platform-301659879.html
SOURCE Mercury Bio LLC
Jasper Commerce Inc. (TSXV: JPIM) ("Jasper"or the "Company"), a leading provider of Product Information Management ("PIM") solutions, announces that management and directors acquired 380,000 common shares of Jasper in the open market between October 14 and October 24, at prices ranging from $0.05 to $0.10 per share. Complete details are available at SEDI.ca. With the Company expected to file its audited annual financial statements and related MD&A for the fiscal year ending July 31 2022 at the e
Merck will soon share its positive phase 3 clinical trial results for a rare disease drug candidate at an upcoming event.
Inflation is 8.3%, medical costs are up by 5.4%, the average hospital stay for Medicare patients is $13,600 and the most recent estimate is that people aged 65 will pay $315,000 for medical care during their retirement years. So what's … Continue reading → The post Here's Why Retirees Can Breathe a Sigh of Relief appeared first on SmartAsset Blog.
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of updated clinical data from the first two cohorts of the Phase 1/2 study of ESSA's lead candidate EPI-7386 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer ("mCRPC"). Data will be presented in a poster format at the 2022 Prostate Cancer Fou
The 20-year old investor who found fame this year when he made $110 million from trading the stock of troubled retailer Bed Bath & Beyond Inc., has turned activist shareholder and is pushing for changes at psychedelics company Mind Medicine Inc.
Take action instead of just crossing off the days until you turn 65.
When it comes to Medicare, understanding your healthcare needs and finding the right coverage are essential. But as you get close to or enter retirement, making decisions about your health can be overwhelming. To make the process a little easier, Vanguard … Continue reading → The post Vanguard's 3 Steps to Maximizing Your Medicare Coverage appeared first on SmartAsset Blog.
The companies said last month that their new experimental therapy, called lecanemab, slowed cognitive decline by 27% in a Phase 3 clinical trial.
Tricida only pursued a single drug candidate. That backfired spectacularly, but the drug developer deserves credit on one key measure.
Every year, roughly 697,000 people die from heart disease in the U.S., accounting for one in every five deaths in the nation. Though it is considered the number one cause of mortality in both women and men, there are many ways you can reduce your personal risk of a coronary condition. In particular, lowering certain cardiometabolic risk factors such as your blood sugar, blood pressure, and low-density lipid (LDL) can significantly slash your risk—and experts say you may be able to see improvemen
AstraZeneca Plc (NASDAQ: AZN) shared positive topline data from the CAPItello-291 Phase 3 trial of capivasertib in combination with Faslodex (fulvestrant) in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-low or negative locally advanced or metastatic breast cancer patients, following recurrence or progression on or after endocrine therapy. The capivasertib + Faslodex combo demonstrated a statistically significant and clinically meaningful improvement in progress
AbbVie's Humira, used to treat inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, has been the world's top-selling drug for years. Now, Eli Lilly (NYSE: LLY) and Bristol Myers Squibb (NYSE: BMY) have blockbuster drugs in the works that could also change lives and boost their companies' fortunes. Lilly's Mounjaro (tirzepatide), a once-weekly injection, received its first Food and Drug Administration (FDA) approval in May as a therapy to treat type 2 diabetes, but the therapy also has huge potential as a weight-loss drug.
Turning 50 and beyond is truly a fun stage of life when your body's prepared to enjoy it fully. In order to stay healthy, fit, and live your absolute best life, it's important now more than ever before to stay active and incorporate exercise into your routine. To help you out, we've put together some crucial morning exercises you shouldn't skip after 50, according to science.Working out can help you build muscle as well as torch calories. By staying on top of your fitness game, you'll also limit
After being given a poisoned IV bag during a routine surgery, a teenager in Texas was given an almost $13,000 bill, which his family has contested.
Here’s what you need to know.
A petition was filed requesting that the FDA initiate proceedings to withdraw approval of all medications containing lurbinectedin, currently marketed under the brand Zepzelca by Jazz Pharmaceuticals plc (NASDAQ: JAZZ). The FDA granted accelerated approval to lurbinectedin in June 2020 for metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Continued approval for this indication may be contingent upon verification and description of clinical
A cancer diagnosis is shocking and scary for anyone, just as it was for Dr. Jennifer Callaway.
Select cleaning products meant to rid homes of harmful germs may leave already sick people vulnerable to a new infection. Clorox is recalling a handful of its scented Pine-Sol products due to a contanimation bacteria that can lead to serious infection for people with weakened immune systems. The voluntary recall, announced by the company Tuesday, does not include Original Pine-Sol, in pine scent.
The good news keeps coming in for Biogen (NASDAQ: BIIB). On Tuesday, the drugmaker reported its third-quarter results, and for the first time in a while, investors found something in one of its earnings updates to cheer about.
A North Carolina state treasurer’s report found hospitals give conflicting information about whether they profit from Medicare patients.

source

Add a Comment

Your email address will not be published. Required fields are marked *